Pay in 4 interest-free payments of $5.66 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
Share: A new study from the University of California San Diego suggests that glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications originally developed for type 2 diabetes, may have benefits that extend far beyond blood sugar and weight management
For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied
This early improvement is especially valuable for those recovering from fractures or bone-related surgeries
Table 1 shows the results of GLP-1 RA use on psoriasis patients across randomized controlled trials, case reports, cohort studies, and meta-analyses
This work was supported by Fundacin de la Asociacin Espaola contra el Cncer (AECC) grant PROYE20060CAMP to M.R.C., grant PID2022-138880OB-I00 funded by MCIN /AEI /10.13039/501100011033 / FEDER, UE to M.L.T., grant PID2020-115218RB-I00 funded by MCIN/AEI/10.13039/501100011033 to T.I., and Instituto de Salud Carlos III (CIBERNED) to T.I
US$ 25.10
US$ 23.56
US$ 28.70
US$ 24.15
US$ 29.34
US$ 25.36
US$ 26.58
US$ 20.40
US$ 26.49
US$ 20.70
US$ 26.00
US$ 21.98
